SBMU, Pharmaceutical Research Sciences
  • Register
  • Login
International Pharmacy Acta
  • Home
  • Journal Info
    • About
    • Aim and Scope
    • Ownership & Management
    • Indexing
    • Editorial Team
  • New Submission
  • Author Guidelines
    • Guideline
    • Types of articles
    • Templates
    • Publication Fees
  • Policies and Process
    • Publication Policy
    • Peer Review Process
    • Open Access Policy
    • plagiarism
    • Archiving
    • Privacy Statement
    • Copyright Notice
    • Waiver policy
    • Complaints Policy
    • Post- Publication Discussions and Corrections Policy
    • Advertisement and Marketing
  • Issues
    • Current
    • Archives
  • Contact us
Advanced Search
  1. Home
  2. Archives
  3. Vol. 1 No. 1 (2018): Pharmacy Updates 2018 (Congress Proceeding)
  4. Supplementary Issues: Reviews of books, journal, congress, other media Special issues, and Scientific news

Vol. 1 No. 1 (2018)

March 2018

Recombinant production of Annexin V protein for apoptosis detection to monitor cancer therapy

  • Mahdiye zaboli
  • Masoud Torkzadeh Mahani

International Pharmacy Acta, Vol. 1 No. 1 (2018), 4 March 2018 , Page 55-56
https://doi.org/10.22037/ipa.v1i1.19929 Published: 2018-03-04

  • View Article
  • Download
  • Cite
  • Statastics
  • Share

Abstract

Introduction:

Apoptosis or programmed cell death (PCD) plays an important role not only in physiology but also in pathology. One of the most prominent features of apoptosis is externalization of phosphatidylserine (PS), which in healthy cells are located in the inner leaflet of the plasma membrane. PS-externalization have made a well-explored phenomenon to image cell death for diagnostic and therapeutic purposes. Since many drugs induce a therapeutic effect through the activation of PCD in target cells, imaging of cell death offers a direct way to image therapy response. Moreover, failure of therapy is frequently a result of resistance against apoptosis. Therefore detection and quantification of apoptosis are some of the significant clinical value for diagnosis and assessment for  therapeutic efficacy. In this research we emphasize the expression and purification of recombinant polyhistidine-tagged human annexin V protein that binds to PS with high affinity and has been developed as a molecular imaging agent to measure cell death in vitro and  in vivo in animal models and in patients with cardiovascular diseases and cancer. We also describe conjugation of this protein to the Fluorescein isothiocyanate (FITC) fluorophore for the detection of apoptotic cells by flow cytometry or fluorescence microscopy.

Methods and Results:

In this project we transformed recombinant plasmid including annexin V gene into competent BL21 strain. after an overnight incubation at 37°C in LB medium,1 mL of that was used to inoculate 100 mL of TB culture.

The expression of annexin V was induced with 1 mM IPTG (isopropyl-b-D-thiogalactopyranoside).

The expression level of annexin V was evaluated by SDS-PAGE. Recombinant annexin V was expressed and purified to high yields. FITC as the fluorescent conjugate and a signal detector was used to attach to annexin V. we detected apoptotic cells in culture by annexin V-FITC produced probe in real time, using fluorescence microscopy and flow cytometry.

 Conclusions:

Annexin V staining is a simple and widely used method for detection of apoptosis in a rapid and highly quantitative manner for both early monitoring of therapy capability and assessment of disease development.

Keywords:
  • Apoptosis, Annexin V, PS, FITC, Cancer therapy
  • PDF

How to Cite

zaboli, M., & Torkzadeh Mahani, M. (2018). Recombinant production of Annexin V protein for apoptosis detection to monitor cancer therapy. International Pharmacy Acta, 1(1), 55–56. https://doi.org/10.22037/ipa.v1i1.19929
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX
  • Abstract Viewed: 298 times
  • PDF Downloaded: 184 times

Download Statastics

  • Linkedin
  • Twitter
  • Facebook
  • Google Plus
  • Telegram

Information

  • For Readers
  • For Authors
  • For Librarians

Make a Submission

Make a Submission
  • Home
  • Archives
  • Submissions
  • About the Journal
  • Editorial Team
  • Contact

Creative Commons License
This journal (and its contents) is licensed under a  Creative Commons Attribution-NonCommercial 4.0 International License.

 

                                                  Online ISSN: 2645-3266

                                                  Print ISSN: 2645-3258                                                 

Powered by OJSPlus